The company sources active pharmaceutical ingredients (APIs) for cretostimogene and manufactures cretostimogene in the United States. It uses specialized laboratory equipment, supplies, materials, and precursor compounds that may be obtained from multiple countries outside the United States. Trade restrictions, tariffs, and political tensions could increase costs, disrupt supply chains, delay development timelines, and complicate compliance with trade regulations, potentially affecting the company's growth, competitiveness, and financing capacity.
Cg Oncology Inc's Comment on Supply Chain
The company sources active pharmaceutical ingredients (APIs) for cretostimogene and manufactures cretostimogene in the United States. It uses specialized laboratory equipment, supplies, materials, and precursor compounds that may be obtained from multiple countries outside the United States. Trade restrictions, tariffs, and political tensions could increase costs, disrupt supply chains, delay development timelines, and complicate compliance with trade regulations, potentially affecting the company's growth, competitiveness, and financing capacity.
Sources:
Cg Oncology Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Cg Oncology Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
